Neuland Laboratories Ltd.
NSE: NEULANDLAB · Pharmaceuticals
Snapshot
Unlock Neuland Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Neuland Laboratories Limited is a pharmaceutical company specialising in the manufacture and sale of active pharmaceutical ingredients (APIs) across diverse therapeutic areas. The company also provides custom manufacturing solutions and peptide synthesis services to global clients.
Business Model
The company generates revenue through the production and supply of APIs for various medical conditions and by offering contract development and manufacturing services. It leverages its technical expertise in complex chemistry to serve international markets including Europe and the United States.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the expansion of custom manufacturing solutions and the increasing demand for specialised peptide synthesis services. The company continues to leverage its established presence in international markets to scale its API portfolio.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where any failure to meet quality standards could lead to import bans or operational disruptions.
- Foreign Exchange Volatility. As a significant portion of revenue is derived from international markets, fluctuations in currency exchange rates can impact profitability.
- Supply Chain Dependency. Reliance on external suppliers for key raw materials and intermediates exposes the company to potential supply chain bottlenecks and price volatility.
- Competitive Pricing. The global API market is highly competitive, which may exert pressure on profit margins due to aggressive pricing strategies by other manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Neuland Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,372 Cr
TTM · consolidated
NET PROFIT
₹498 Cr
TTM · consolidated
EPS
₹387.97
TTM · consolidated
RETURN ON EQUITY
29.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
35.4%
TTM · consolidated
P/E
58.4x
Q1 FY27 · consolidated
EV/EBITDA
36.8x
Q1 FY27 · consolidated
EBITDA MARGIN
33.5%
TTM · consolidated
NET PROFIT MARGIN
23.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Neuland Laboratories Ltd.NEULANDLAB | ₹29,073 Cr | 58.41 | 36.78 | 78.3% | 33.5% | 29.3% | 35.4% | +55.1% |
Wockhardt Ltd.WOCKPHARMA | ₹33,940 Cr | 82.88 | 40.10 | 18.4% | 25.1% | 8.9% | 10.4% | +41.5% |
Sai Life Sciences Ltd.SAILIFE | ₹33,605 Cr | 92.27 | 47.96 | — | 31.2% | 15.7% | 19.8% | +86.7% |
Rubicon ResearchRUBICON | ₹29,245 Cr | 99.68 | 63.32 | — | 23.9% | 22.4% | 27.6% | — |
Piramal Pharma Ltd.PPLPHARMA | ₹28,520 Cr | -90.39 | 26.16 | 0.8% | 13.6% | -3.9% | 1.4% | +7.7% |
Acutaas Chemicals LtdACUTAAS | ₹25,941 Cr | 67.17 | 45.18 | 40.9% | 39.0% | 26.1% | 34.3% | +122.4% |
As of Q1 FY27
Financials
Neuland Laboratories Ltd.
NSE: NEULANDLAB · Pharmaceuticals
Snapshot
Unlock Neuland Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Neuland Laboratories Limited is a pharmaceutical company specialising in the manufacture and sale of active pharmaceutical ingredients (APIs) across diverse therapeutic areas. The company also provides custom manufacturing solutions and peptide synthesis services to global clients.
Business Model
The company generates revenue through the production and supply of APIs for various medical conditions and by offering contract development and manufacturing services. It leverages its technical expertise in complex chemistry to serve international markets including Europe and the United States.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the expansion of custom manufacturing solutions and the increasing demand for specialised peptide synthesis services. The company continues to leverage its established presence in international markets to scale its API portfolio.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where any failure to meet quality standards could lead to import bans or operational disruptions.
- Foreign Exchange Volatility. As a significant portion of revenue is derived from international markets, fluctuations in currency exchange rates can impact profitability.
- Supply Chain Dependency. Reliance on external suppliers for key raw materials and intermediates exposes the company to potential supply chain bottlenecks and price volatility.
- Competitive Pricing. The global API market is highly competitive, which may exert pressure on profit margins due to aggressive pricing strategies by other manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Neuland Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,372 Cr
TTM · consolidated
NET PROFIT
₹498 Cr
TTM · consolidated
EPS
₹387.97
TTM · consolidated
RETURN ON EQUITY
29.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
35.4%
TTM · consolidated
P/E
58.4x
Q1 FY27 · consolidated
EV/EBITDA
36.8x
Q1 FY27 · consolidated
EBITDA MARGIN
33.5%
TTM · consolidated
NET PROFIT MARGIN
23.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27